Updates are available Correction dated 2023-01-19
Click to view Correction: https://doi.org/10.1038/s41572-023-00418-5
-
Authors
Johnson, Daniel E.
Burtness, Barbara
Leemans, C. René
Lui, Vivian Wai Yan
Bauman, Julie E.
Grandis, Jennifer R.
- License Information
-
More Information
Article History
Accepted: 1 October 2020
First Online: 26 November 2020
Change Date: 19 January 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41572-023-00418-5
Competing interests
: D.E.J. and J.R.G. are co-inventors of cyclic STAT3 decoy and have financial interests in STAT3 Therapeutics. STAT3 Therapeutics holds an interest in cyclic STAT3 decoy. B.B. has received honoraria for consulting from Merck and AstraZeneca. C.R.L. serves on the Advisory Board of Merck & Co. and Rakuten Medical. V.W.Y.L. receives grant support from Lee’s Pharmaceutical, Hong Kong Limited, via the University–Industry Collaboration Program (UIM/329; from the Innovation and Technology Fund, Hong Kong Government; in 2018–2020), and served as a scientific consultant for Novartis Pharmaceutical (Hong Kong) Limited (Oct 2015–Oct 2016). J.E.B. serves as a scientific consultant to CUE Pharmaceuticals and AstraZeneca and has research grant support from the IST programmes of Aveo and Novartis.
